Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead

Vir Biotechnology is approaching a catalyst-rich period with readouts from the company's trials in hepatitis delta and oncology ahead. In February, I rated VIR a "Hold" based on the difficulty of predicting This article was written by Biotech Beast 9.25K Followers Follow Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice. Analyst’s Disclosure: I/we have a beneficial long position in the shares of VIR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.